Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.
about
Twenty years of anti-HER2 therapy-associated cardiotoxicityCancer treatment-related cardiac toxicity: prevention, assessment and management.Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.Biological agents in gastrointestinal cancers: adverse effects and their management.Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab.Adjuvant trastuzumab: a 10-year overview of its benefit.Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.Trastuzumab-associated cardiac events in the Persephone trial.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Targeting the mTOR pathway in breast cancer.ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summaryThe real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan.Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.Hypertension in malignancy-an underappreciated problem.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.
P2860
Q28079391-4AB33AF4-358F-4A5A-B6C6-9A3735B01802Q30276456-9A42DA9D-EDBA-43AE-BCB9-0AE55F9102DDQ33600072-BAF41E8B-53C2-4200-8ECF-2102E0DBD370Q33895581-AD0AFECC-DDAB-4F78-994B-23CB597F1D69Q37735969-864ECD72-8F4A-4269-BB88-CC06630F6F18Q39018742-BF53413A-6189-449B-B706-F51336F762FBQ39078275-2ADC4D47-76D1-44C4-B36A-A712335B92E6Q39163356-91A4AAF6-7207-455E-B40A-378FCDA3F107Q39375196-F4D0EBA7-D0ED-474C-8475-15DB42D188C7Q39390640-2C1E9D0F-AD20-4CE2-A792-F7F885A2EC4FQ41082970-B45745C7-1FEE-4344-A4A4-F646ACB4696EQ48056637-D7E13D82-EAD3-41E1-B891-8A28FCA19700Q48212195-CC68A5E0-E3AB-42AE-824C-8F4D072389C6Q49961375-FCC4C45C-7423-4A5F-BA02-EAD1BBFFB37DQ55071881-CD24AFEC-EC0F-4209-B0AB-9487048603F4Q55222160-B6AB6210-7A22-4950-A603-9BCE988A9074
P2860
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@ast
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@en
type
label
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@ast
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@en
prefLabel
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@ast
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@en
P2093
P2860
P50
P1476
Risk of severe cardiotoxicity ...... ,000 women with breast cancer.
@en
P2093
Marta Rossi
Martina Bonifazi
Roberto D'Amico
Stefania Mantarro
P2860
P2888
P304
P356
10.1007/S11739-015-1362-X
P577
2015-12-28T00:00:00Z